Show all
November 6, 2023
PGN-EDODM1 Nonclinical Data Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of Myotonic Dystrophy Type 1 (DM1)
Summary: The Enhanced Delivery Oligonucleotide (EDO) platform is engineered to optimize the tissue penetration, cellular uptake and nuclear delivery of oligonucleotide therapeutic candidates.
November 6, 2023
Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Summary: PGN-EDO51 is PepGen’s clinical-stage EDO candidate for the treatment of people with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
November 6, 2023
FREEDOM-DM1: Nonclinical Data Support the Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1)
Summary: The Enhanced Delivery Oligonucleotide (EDO) platform is engineered to optimize the tissue penetration, cellular uptake and nuclear delivery of oligonucleotide therapeutic candidates.